Alumis Q1 revenue drops, net loss narrows after trial completion

Alumis

14/05/2026 21:30

Overview

US biopharma firm's Q1 revenue fell sharply from prior year due to lower license revenue

Q1 net loss narrowed as R&D and admin expenses declined after Phase 3 trial completion

Company highlighted positive Phase 3 data for envudeucitinib and remains on track for NDA submission in Q4

Outlook

Alumis plans NDA submission for envudeucitinib in psoriasis in 4Q 2026

Company expects Phase 2b SLE topline data for envudeucitinib in 3Q 2026

Alumis expects existing cash to fund operations into 4Q 2027

Result Drivers

LOWER R&D COSTS - Research and development expenses fell after completion of enrollment and reporting of positive topline results for pivotal Phase 3 envudeucitinib trials in psoriasis

LOWER ADMIN COSTS - General and administrative expenses declined due to absence of prior-year merger transaction costs, partly offset by higher personnel expenses

Company press release: ID:nGNX8FybJD

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$93.05 mln
Q1 Income From Operations
-$98.41 mln
Q1 Operating Expenses
$100.15 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Alumis Inc is $38.00, about 52.9% above its May 13 closing price of $24.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)